Log in

ALRTF ALR Technologies SG Ltd. OTC · United States

ALR Technologies SG (ALRTF) news

ALR Technologies SG Ltd. is a public biotech or pharmaceutical company listed on OTC under the ticker ALRTF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest ALR Technologies SG news

We have not published a story on ALR Technologies SG yet. When there is news, it will appear here.

What ALR Technologies SG does

ALR Technologies SG Ltd. describes itself as a data management company with a comprehensive approach to diabetes care. Its Diabetes Solution product collects data from blood glucose meters (BGM) and continuous glucose monitors (CGM), and it is FDA-cleared and HIPAA-compliant. Its technology portfolio also includes a patent pending Predictive A1C algorithm that tracks treatment success between lab reports, and an FDA-cleared Insulin Dosing Adjustment program. The company says it is actively seeking to commence revenue-generating activities for the Diabetes Solution. It also developed GluCurve, a version for animal health, sold as the GluCurve Pet CGM. In 2022 it entered a co-branded distribution agreement with Covetrus, Inc. for the GluCurve Pet CGM, which expired while the company evaluated new CGM suppliers. On September 19, 2025 it entered a manufacturing agreement with CGM Medical Technology Shen Zhen Ltd., subject to the hardware meeting its specifications. Earlier, it agreed with Bionime Corporation to bundle the Diabetes Solution with blood glucose test supplies for private clinics in Singapore, and a 24-week pilot with Singapore General Hospital reported a mean drop of 1.2 percent in HbA1c.

Product or programWhat it isStage
Diabetes SolutionData management product collecting BGM and CGM data for diabetes careFDA-cleared
Insulin Dosage Adjustment technologyInsulin dosing adjustment programFDA-cleared
Predictive A1CAlgorithm tracking treatment success between lab reportspatent application filed under the PCT
GluCurve Pet CGMContinuous glucose monitor for animal healthrelaunch under discussion

Summarised from the company's 20-F filed Apr 30, 2026.

ALR Technologies SG annual financials

LineFY2025FY2024
Research and development$793,327$883,866
Net income (loss)-$22.1 million-$15.9 million
Cash from operations-$1.9 million-$1.5 million
Cash and equivalents$20,305$40,657

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $20,305.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about ALR Technologies SG

What is the ticker symbol of ALR Technologies SG?

ALR Technologies SG Ltd. trades under the ticker ALRTF on OTC.

Where is ALR Technologies SG listed?

ALR Technologies SG Ltd. is listed on OTC.

Which country or territory is ALR Technologies SG listed under?

Our directory records ALR Technologies SG Ltd. under United States.

Does aibio.space cover ALR Technologies SG?

aibio.space lists ALR Technologies SG Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

What does ALR Technologies SG develop?

ALR Technologies SG Ltd. describes itself as a data management company with a comprehensive approach to diabetes care. Its Diabetes Solution product collects data from blood glucose meters (BGM) and continuous glucose monitors (CGM), and it is FDA-cleared and HIPAA-compliant.

What is Diabetes Solution from ALR Technologies SG?

Diabetes Solution: Data management product collecting BGM and CGM data for diabetes care Stage: FDA-cleared.

What is Insulin Dosage Adjustment technology from ALR Technologies SG?

Insulin Dosage Adjustment technology: Insulin dosing adjustment program Stage: FDA-cleared.

Is ALR Technologies SG profitable?

ALR Technologies SG Ltd. reported a net loss of $22.1 million for the fiscal year ended Dec 31, 2025, and used $1.9 million of cash in operations, per its annual report to the SEC.

How much does ALR Technologies SG spend on research and development?

$793,327 in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does ALR Technologies SG have?

$20,305 in cash at Dec 31, 2025, per its 20-F.

Investor discussion: ALR Technologies SG

Members talk about ALR Technologies SG (ALRTF). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:ALRTF on TradingView.

Listing details

ALR Technologies SG Ltd. is a public biotech or pharmaceutical company listed on OTC under the ticker ALRTF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
ALR Technologies SG Ltd.
Ticker
ALRTF
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.